Evidence map›Paper›PMID 35783392›Full record

ArticleFrontiers in microbiology2022

Systematic Approach to Address Early Pandemic's Diagnostic Unmet Needs.

Catherine Cabrera, Kanoelani Pilobello, Steven Dalvin, Johanna Bobrow, Darshi Shah, Lori Freed Garg, Sujata Chalise, Patrick Doyle, Glenn A Miller, David R Walt and 2 more

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Catherine CabreraMassachusetts Institute of Technology Lincoln Laboratory, Lexington, MA, United States.
Kanoelani PilobelloWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, United States.
Steven DalvinWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, United States.
Johanna BobrowMassachusetts Institute of Technology Lincoln Laboratory, Lexington, MA, United States.
Darshi ShahDepartment of Biomedical Engineering, Boston University, Boston, MA, United States.
Lori Freed GargGlobal Health Innovation Lab, Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, United States.
Sujata ChaliseWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, United States.
Patrick DoyleBrigham and Women's Hospital, Boston, MA, United States.
Glenn A MillerMass General Brigham Incorporated, Boston, MA, United States.
David R WaltWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, United States.
Sara SulimanDivision of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Boston, MA, United States.
Pawan JollyWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During the first few months of the global Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic, the medical research community had to expeditiously develop, select, and deploy novel diagnostic methods and tools to address the numerous testing challenges presented by the novel virus. Integrating a systematic approach to diagnostic selection with a rapid validation protocol in a clinical setting can shorten the timeline to bring new technologies to practice. In response to the urgent need to provide tools for identifying SARS-CoV-2-positive individuals, we developed a framework for assessing technologies against a set of prioritized performance metrics to guide device selection. We also developed and proposed clinical validation frameworks for the rapid screening of new technologies. The rubric described here represents a versatile approach that can be extended to future technology assessments and can be implemented in preparation for future emerging pathogens.

Indexed as

COVID-19diagnosticpoint-of-servicerubric systemSARS-CoV-2

Identifiers

PMID35783392
PMCPMC9247567

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.